ArticleRegulatory toxicology and pharmacology : RTP2011
Overview of the marmoset as a model in nonclinical development of pharmaceutical products.
Article in Regulatory toxicology and pharmacology : RTP, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Prediction of Human Serum Concentration-Time Profiles of Golimumab and Ustekinumab Using Pharmacokinetic Data From Common Marmosets With Assessment of Anti-Drug Antibodies.Biopharmaceutics & drug disposition · 2026Article
- Histological characterization of major internal organs in infant common marmosets (Callithrix jacchus).PloS one · 2026Article
- Marmosets as models of infectious diseases.Frontiers in cellular and infection microbiology · 2024Review
- The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- The Common Marmoset-Biomedical Research Animal Model Applications and Common Spontaneous Diseases.Toxicologic pathology · 2022Article
- The Innate Immune Response in the Marmoset during the Acute Pneumonic Disease Caused by Burkholderia pseudomallei.Infection and immunity · 2022Article
- Synergistic Promoting Effects of X-Linked Inhibitor of Apoptosis Protein and Matrix on the In Vitro Follicular Maturation of Marmoset Follicles.Tissue engineering and regenerative medicine · 2022Article
- Specific gene expression in unmyelinated dorsal root ganglion neurons in nonhuman primates by intra-nerve injection of AAV 6 vector.Molecular therapy. Methods & clinical development · 2021Article
- Comparison of Genetically Engineered Immunodeficient Animal Models for Nonclinical Testing of Stem Cell Therapies.Pharmaceutics · 2021Review
- Advancing Autism Research From Mice to Marmosets: Behavioral Development of Offspring Following Prenatal Maternal Immune Activation.Frontiers in psychiatry · 2021Article
- Marmosets: Welfare, Ethical Use, and IACUC/Regulatory Considerations.ILAR journal · 2020Review
- Utility of Common Marmoset (Genes · 2020Review
- Article
- Aging research using the common marmoset: Focus on aging interventions.Nutrition and healthy aging · 2019Article
- Multimodal assessments of Zika virus immune pathophysiological responses in marmosets.Scientific reports · 2018Article
- Thioacetamide-induced hepatic fibrosis in the common marmoset.Experimental animals · 2018Article
- A Novel Translational Model of Spinal Cord Injury in Nonhuman Primate.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2018Article
- Why the macula?Eye (London, England) · 2018Review
- Polymorphism of the 3'-UTR of the dopamine transporter gene (DAT) in New World monkeys.Primates; journal of primatology · 2017Article
- Use of nonhuman primates for the development of bioengineered female reproductive organs.Tissue engineering and regenerative medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Callithrix jacchus (common marmoset) is one of the more primitive non-human primate species and is used widely in fundamental biology, pharmacology and toxicology studies. Marmosets breed well in captivity with good reproductive efficiencies and their sexual maturity is reached within 18 months of age allowing for rapid expansion of colonies and early availability of sexually mature animals permitting an earlier assessment of product candidates in the adult. Their relatively small size allows a reduction in material requirements leading to a reduction in development time and cost. Fewer animals are also required due to their ability to be used in both pharmacology and toxicology (nonclinical) studies. These factors, alongside a better understanding of their optimal nutrient and welfare requirements over recent years, facilitate the generation of a more cohesive and robust dataset. With the growth of biotechnology-derived pharmaceuticals, non-human primate use has, by necessity, also increased; nevertheless, there is also a growing public call for minimizing their use. Utilizing, the more primitive marmoset species may provide the optimal compromise and once the scientific rationale has been carefully considered and their use justified, there are several advantages to using the marmoset as a model in nonclinical development of pharmaceutical products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.